Art. -Nr.: HY-N0125

Diosmetin

21 Cited Publications

Kundenbewertung

Based on 21 publication(s) in Google Scholar

Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity with an IC₅₀ of 40 μM in HepG2 cell.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.71%
CAS. Nr.: 520-34-3
Formel: C₁₆H₁₂O₆
Molecular Weight:300.26

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Diosmetin Chemical Structure

CAS. Nr.: 520-34-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (21)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity with an IC₅₀ of 40 μM in HepG2 cell.

IC₅₀ & Target

CYP1

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	EC₅₀	7.98 μM Compound: Diosmetin	Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay	[PMID: 26974372]
HepG2	EC₅₀	7.98 μmol Compound: Diosmetin	Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay	[PMID: 26974372]
HT-22	EC₅₀	59.7 μM Compound: 12	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
HUVEC	IC₅₀	7.6 μM Compound: 40, diosmetin	Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells	10.1007/s00044-012-0353-y
K562	IC₅₀	8.42 μM Compound: Diosmetin	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay	[PMID: 35551036]
KBM5	IC₅₀	6.46 μM Compound: Diosmetin	Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay	[PMID: 35551036]
KBM5	IC₅₀	8.52 μM Compound: Diosmetin	Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay	[PMID: 35551036]
Monocyte	IC₅₀	3 μM Compound: diosmetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	3 x 10^-6 M Compound: diosmetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Neutrophil	IC₅₀	0.7 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	10.3 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	15 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	3.6 μM Compound: 4g, Diosmetin	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Peritoneal macrophage	IC₅₀	8.9 μM Compound: 28; kp18	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	16.7 μM Compound: 28; kp18	Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	32.2 μM Compound: 28; kp18	Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	8.4 μM Compound: 10	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
RAW264.7	CC₅₀	>100 μM Compound: 19	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33667099]
RAW264.7	IC₅₀	34.5 μM Compound: 19	Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 33667099]

In Vitro

Diosmetin inhibits cell proliferation in HepG2 cells in a concentration-dependent manner. Untreated HepG2 cells grow well and are observed to have with normal skeletons, whereas cells treated with diosmetin are distorted and a number of them become round and floating^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pretreatment with diosmetin significantly reduces serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-κB activation in cerulein-induced acute pancreatitis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 520-34-3
Appearance Solid
Molecular Weight 300.26
Formel C₁₆H₁₂O₆
Color Light yellow to yellow
SMILES

O=C1C=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13
Structure Classification
- Flavonoids
- Flavones
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (21)

All Cell Proliferation/Viability AssayCell Migration/Invasion AssayWBHistological Imaging/StainingOthers

Sort by:

Journal Impact Factor

Phytomedicine

Diosmetin alleviates the immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma by dually inhibiting angiogenesis and promoting CD8+T cell cytotoxicity. [Abstract]

2026 May:154:158036. PMID: 41830859

Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]

IC50 values of ESCC cells after 48 h of Diosmetin (DIOS) treatment.

Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]

Effects of Diosmetin (DIOS) pretreated ESCC cell conditioned medium (CM) on migration, invasion, and tubular formation of human umbilical vein endothelial cells (HUVECs).

Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]

The expression levels of p-PI3K Tyr458, p-AKT Ser473, p-STAT4 Tyr693, and PDGFC, as well as the secretion level of PDGFC, were detected in ESCC cells after Diosmetin (DIOS) intervention.

Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]

Diosmetin (DIOS: 40 μM). Immunohistochemical staining image of CD31 in glue plug tissue.

Diosmetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 May:154:158036. [Abstract]

SPR experiments showed that Diosmetin (DIOS: 40 μM) can bind directly to AURKB.
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 Oct 15:489:144992. PMID: 40466530
Int J Mol Med

Targeting p38 MAPK signaling pathway: Quercetin as a novel therapy for TMJ synovitis. [Abstract]

2026 Jan;57(1):21. PMID: 41235659
Ind Crops Prod

2026 May 8;246:123392.
Int J Mol Sci

Elucidating the Mechanisms of Chrysanthemum Action on Atopic Dermatitis via Network Pharmacology and Machine Learning. [Abstract]

2025 Nov 21;26(23):11262. PMID: 41373428
Int Immunopharmacol

Diosmetin alleviates acute kidney injury by promoting the TUG1/Nrf2/HO-1 pathway in sepsis rats. [Abstract]

2020 Nov:88:106965. PMID: 33182044
Sci Rep

Targeting the p38/MAPK pathway to induce apoptosis: a multidimensional mechanistic exploration of Mentha and its active compound diosmetin against liver cancer. [Abstract]

2025 Nov 11;15(1):39432. PMID: 41219344
J Cell Mol Med

Immunomodulatory Mechanism of Baiyaojian Decoction on Periodontitis: Network Pharmacology, Single-Cell RNA Sequencing and Molecular Docking. [Abstract]

2026 Feb;30(3):e71034. PMID: 41605874
FASEB J

Effect of Diosmetin on Gut Microbiota and Serum Metabolites in Acute Pancreatitis Mice: A Metagenomic and Metabolomic Study. [Abstract]

2026 Mar 31;40(6):e71679. PMID: 41854683
Dermatol Clin

2025 August 20.
Animals (Basel)

Diosmetin Delays In Vitro Aging of Porcine Oocytes by Improving Mitochondrial Function and Reducing Oxidative Stress. [Abstract]

2025 Jan 21;15(3):291. PMID: 39943061
Food Chem Toxicol

The "steric-like" inhibitory effect and mechanism of doxycycline on florfenicol metabolism: Interaction risk. [Abstract]

2022 Nov:169:113431. PMID: 36116547
J Nat Med

Diosmetin alleviates osteoarthritis through modulating the polarization of macrophages by inhibiting the PI3K/Akt signaling pathway. [Abstract]

2025 Sep;79(5):1030-1043. PMID: 40702221
Thorac Cancer

Diosmetin Inhibits NETs Formation in Neutrophils Through Regulating Nrf2 Signaling. [Abstract]

2025 Mar;16(6):e70040. PMID: 40110767
Mol Reprod Dev

Diosmetin Promotes Early Embryonic Development in Pigs by Alleviating Oxidative Stress. [Abstract]

2024 Sep;91(9):e23775. PMID: 39350355
Folia Histochem Cytobiol

Diosmetin ameliorates osteoarthritic inflammation in vivo and ECM macromolecules degradation in interleukin-1β-stimulated murine chondrocytes through the Nrf2/NF-κB pathway. [Abstract]

2024;62(2):99-109. PMID: 38912570
Biol Pharm Bull

Regioselective Glucuronidation of Flavones at C5, C7, and C4' Positions in Human Liver and Intestinal Microsomes: Comparison among Apigenin, Acacetin, and Genkwanin. [Abstract]

2022;45(8):1116-1123. PMID: 35908893
Res Sq

2024 Jun 06.
Biomed Pharmacother

Diosmetin alleviates neuropathic pain by regulating the Keap1/Nrf2/NF-κB signaling pathway. [Abstract]

2024 Jan:170:116067. PMID: 38150877
Chemosphere

A proposed "steric-like effect" for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism. [Abstract]

2021 Dec:284:131347. PMID: 34323809

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (333.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3304 mL

16.6521 mL

33.3041 mL

5 mM

0.6661 mL

3.3304 mL

6.6608 mL

10 mM

0.3330 mL

1.6652 mL

3.3304 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 10 mg/mL (33.30 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Diosmetin is dissolved in DMSO which is maintained at a constant concentration in control samples (2%). HepG2 cells are maintained in a humidified atmosphere of 5% CO₂ at 37°C, and cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin and 100 U/mL streptomycin. HepG2 cell density is adjusted to 2×10⁴ cells/100 μL, and the cells are seeded into 96-well plates and placed in an incubator overnight (37°C in 5% CO₂) to allow for attachment and recovery. MTT analyses are performed. Briefly, cells are pretreated with 5, 10, 15 and 20 μg/mL diosmetin for 24 h. A total of 20 μL MTT solution (5 mg/mL in PBS) solution is transferred to each well to yield a final 120 μL/well and to separate wells a total of 10 μL CCK8 (5 mg/mL in PBS) is transferred. The plates are incubated for 4 h at 37°C in 5% CO₂ and the absorbance is recorded at wavelengths of 595 nm and 450 nm, respectively. The half maximal inhibitory concentration (IC₅₀) of diosmetin is calculated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Experimental acute pancreatitis is induced in mice by seven intraperitoneal injection of cerulein (50 μg/kg) at hourly intervals. Diosmetin (100 mg/kg) or vehicle is pretreated 2 h before the first cerulein injection. After 6 h, 9 h, 12 h of the first cerulein injection, the severity of acute pancreatitis is evaluated biochemically and morphologically^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Liu B, et al. Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells. Mol Med Rep. 2016 Jul;14(1):159-64. [Content Brief]

[2]. Yu G, et al. Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2133-42. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3304 mL	16.6521 mL	33.3042 mL	83.2604 mL
	5 mM	0.6661 mL	3.3304 mL	6.6608 mL	16.6521 mL
	10 mM	0.3330 mL	1.6652 mL	3.3304 mL	8.3260 mL
	15 mM	0.2220 mL	1.1101 mL	2.2203 mL	5.5507 mL
	20 mM	0.1665 mL	0.8326 mL	1.6652 mL	4.1630 mL
	25 mM	0.1332 mL	0.6661 mL	1.3322 mL	3.3304 mL
	30 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	40 mM	0.0833 mL	0.4163 mL	0.8326 mL	2.0815 mL
	50 mM	0.0666 mL	0.3330 mL	0.6661 mL	1.6652 mL
	60 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL
	80 mM	0.0416 mL	0.2082 mL	0.4163 mL	1.0408 mL
	100 mM	0.0333 mL	0.1665 mL	0.3330 mL	0.8326 mL

Keywords

Diosmetin

21 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Diosmetin

Antioxidant Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Mitochondria-Targeted Compound Library

Food-Sourced Compound Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Radioprotector Library

Radiosensitizer Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Diosmetin

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (21)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Diosmetin Related Classifications

HY-N0125 Related Classifications